RNTECH and DNAVision Announce Co-Marketing Agreement
News Feb 01, 2006
DNAVision and RNTECH have announced that they have signed a co-marketing agreement under which the companies will jointly offer an integrated package of high quality material biological bank, gene expression and genotyping technologies.
Post-genome era discovery processes must be based upon the combination of two key components: high quality, severely selected biological material associated with diagnostic and clinical data from large scale patient cohorts and platforms including genomics, proteomics and bioinformatics platforms.
The RNTECH/DNAVision offer associates these key components, creating an opportunity for pharmaceutical and biotechnology industries to access discovery and development expertise at an unparalleled level in oncology for biomarker and drugable target discovery and development.
"We are delighted to combine our extensive biological material bank in oncology with DNAVision’s gene expression and high-throughput genotyping platforms and offer, what we believe, a unique pharmacogenomic solution to pharmaceutical, clinical, and academic partners interested by finding new biomarkers in oncology," said Michael Bia, CEO of RNTECH.
"We believe that the quality of RNTECH’s biobank with complete clinical data and patient follow-up will provide in combination with our expertise a stronger, more clinically relevant offering for the oncology marketplace," said Jean-Pol Detiffe, CEO of DNAVision.
As genome editing technologies advance toward clinical therapies, they are raising hopes of a completely new way to treat disease. However, challenges need to be addressed before potential treatments can be widely used in patients. To tackle these challenges, the National Institutes of Health has launched the Somatic Cell Genome Editing program, which has awarded multiple grants including more than $3.6 million to assess the safety of genome editing in human cells and tissues.